相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation
Fabrizio Chiti et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2022)
Markov state models and NMR uncover an overlooked allosteric loop in p53
Emilia P. Barros et al.
CHEMICAL SCIENCE (2021)
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm
Matthias R. Bauer et al.
ACS CHEMICAL BIOLOGY (2020)
Systematic Study of the Glutathione Reactivity of N-Phenylacrylamides: 2. Effects of Acrylamide Substitution
Adam Birkholz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
Steffen Boettcher et al.
SCIENCE (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Understanding p53 functions through p53 antibodies
Kanaga Sabapathy et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines
Matthias G. J. Baud et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
The reactivity-driven biochemical mechanism of covalent KRAS(G12C) inhibitors
Rasmus Hansen et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
The reactivity-driven biochemical mechanism of covalent KRAS(G12C) inhibitors
Rasmus Hansen et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2018)
p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo
Evguenia M. Alexandrova et al.
CELL DEATH & DISEASE (2017)
GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease
Donna Oksenberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells
Matthias R. Bauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Clinical Overview of MDM2/X-Targeted Therapies
Andrew Burgess et al.
FRONTIERS IN ONCOLOGY (2016)
Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors
Mark E. Flanagan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Li-Fraumeni syndrome: cancer risk assessment and clinical management
Kate A. McBride et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Paul D. Adams et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Frank M. Boeckler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
Andreas C. Joerger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains
Hwee Ching Ang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy
AN Bullock et al.
ONCOGENE (2000)